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Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention in the last decade as potential targeted
cancer therapies. However, little is known about the molecular determinants of cancer cell sensitivity to FASN inhibitors (FASNis),
which is a major roadblock to their therapeutic application. Here, we find that pharmacological starvation of endogenously
produced FAs is a previously unrecognized metabolic stress that heightens mitochondrial apoptotic priming and favors cell death
induction by BH3 mimetic inhibitors. Evaluation of the death decision circuits controlled by the BCL-2 family of proteins revealed
that FASN inhibition is accompanied by the upregulation of the pro-death BH3-only proteins BIM, PUMA, and NOXA. Cell death
triggered by FASN inhibition, which causally involves a palmitate/NADPH-related redox imbalance, is markedly diminished by
concurrent loss of BIM or PUMA, suggesting that FASN activity controls cancer cell survival by fine-tuning the BH3 only proteins-
dependent mitochondrial threshold for apoptosis. FASN inhibition results in a heightened mitochondrial apoptosis priming, shifting
cells toward a primed-for-death state “addicted” to the anti-apoptotic protein BCL-2. Accordingly, co-administration of a FASNi
synergistically augments the apoptosis-inducing activity of the dual BCL-XL/BCL-2 inhibitor ABT-263 (navitoclax) and the BCL-2
specific BH3-mimetic ABT-199 (venetoclax). FASN inhibition, however, fails to sensitize breast cancer cells to MCL-1- and BCL-XL-
selective inhibitors such as S63845 and A1331852. A human breast cancer xenograft model evidenced that oral administration of
the only clinically available FASNi drastically sensitizes FASN-addicted breast tumors to ineffective single-agents navitoclax and
venetoclax in vivo. In summary, a novel FASN-driven facet of the mitochondrial priming mechanistically links the redox-buffering
mechanism of FASN activity to the intrinsic apoptotic threshold in breast cancer cells. Combining next-generation FASNis with BCL-
2-specific BH3 mimetics that directly activate the apoptotic machinery might generate more potent and longer-lasting antitumor
responses in a clinical setting.
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INTRODUCTION
Elevated de novo fatty acid (FA) biogenesis driven by the activation
of lipogenic enzymes is one of the most common metabolic traits
that provide proliferative and survival advantages to tumors [1–7].
Fatty acid synthase (FASN) is a key enzyme in the endogenous
lipogenesis pathway that primarily catalyzes the synthesis of the
long-chain saturated FA palmitate from acetyl-CoA and malonyl-
CoA, using NADPH as a reducing agent [8–11]. FASN activation is an
early and near universal hallmark of most human carcinomas and
their precursor lesions, and is enhanced in a stage-dependent
manner that associates with worsened patient survival and
therapeutic resistance. Interest in FASN-driven lipid signaling as a
target for therapeutic intervention stemmed from findings more
than a decade ago that tumor cells show reduced growth and
viability upon targeted FASN suppression [8, 9, 11–14]. Since then,
however, we have been unable to resolve the discrepancy between
the basic science-discovery bench aspects of FASN blockade and the
awaited bedside effects of FASN inhibitors (FASNis).
The demonstration of target engagement and early signs of
clinical activity in cancer patients receiving next-generation
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FASNis—TVB-2640 [11]—has reignited interest in FASN as a target
for new drug development. Unfortunately, the molecular deter-
minants of cancer cell sensitivity to FASNis are unclear, mostly
because the biological mechanisms responsible for FASNis-
induced cell death are largely unknown [8–14]. Cancer cells can
satisfy their demand for FAs by active uptake from the blood-
stream [15], and the requirement of FASN in malignant
transformation would be unrelated to its capacity to cell-
autonomously generate endogenous lipids [16]. FASN activity
accounts for the highest cell consumption of not only NADPH but
also acetyl-CoA [8], thereby unlocking IDH1-dependent reductive
carboxylation to ensure the production of reduced equivalents to
counterbalance the mitochondrial oxidative stress and overcome
anoikis [17–20]. Whether the essentiality of FASN to generate the
necessary reductive power to quench an excessive production of
reactive oxygen species (ROS) might similarly explain why FASNis
ultimately determine if the mitochondrial apoptotic pathway is
activated or not [21–25] remains unexplored.
Here, we hypothesized that the intrinsic variability of cancer
cells to promote mitochondrial oxidative stress and engage the
death decision circuitry controlled by BCL-2 family interactions
centrally contributes to the response to FASNis (Fig. 1). We now
uncover a novel FASN-driven facet of the so-called “mitochondrial
priming” that mechanistically links the redox-buffering mechan-
ism of FASN activity to the intrinsic apoptotic threshold in cancer
cells. We demonstrate that cancer cells treated with FASNis can
acquire a “primed-for-death” mitochondrial state with apoptotic
hypersensitivity to BCL-2 specific BH3-mimetics. The discovery
that starvation of endogenously produced FAs is a metabolic
stress that heightens mitochondrial apoptotic priming might open
a new avenue to rationally use next-generation FASNis and BH3
mimetic drugs for combinatorial optimization in cancer therapy.
MATERIALS AND METHODS
Cell lines
The breast cancer cell lines BT-474, MDA-MB-231, and MCF-7 were obtained
from the ATCC and were maintained in IMEM (Cellgro, Mediatech Inc.,
Manassas, VA) supplemented with 5% fetal bovine serum (FBS, Atlanta
Biologicals, Lawrenceville, GA) at 37°C in a humidified 5% CO2 atmosphere.
Cells were authenticated to ensure their identity using a short tandem
repeat profiling method provided by the Genotyping Shared Resource at
Mayo Clinic Rochester. HAP1 and HAP1 FASN-KO cells (#HZGHC003700c006)
were obtained from Horizon Discovery Ltd. (Cambridge, UK) and
maintained at 37oC with 5% CO2 in IMDM medium (Gibco) supplemented
with 10% FBS, 2mmol/L L-glutamine, and 100 IU/mL penicillin/streptomy-
cin. Cells were tested to confirm the absence of mycoplasma using the
MycoAlert® Mycoplasma Detection Kit (Lonza, Walkersville, MD).
Reagents
Reagents were purchased from the following suppliers: C75 (#2489) from
Tocris Bioscience (Minneapolis, MN); ABT-263/navitoclax (#A3007) from
APExBio (Houston, TX); ABT-199/venetoclax (#CT-A199) from ChemieTek
(Indianapolis, IN); TVB-3166 (#SML1694) from Sigma-Aldrich (St. Louis, MO);
S63845 (#HY-100741) and A1331852 (#HY-19741) from MedChemExpress
(Monmouth Junction, NJ); TVB-3664 was provided by 3V-Biosciences/Sagimet
Biosciences (San Mateo, CA); allophycocyanin (APC)-conjugated annexin V and
binding buffer from BD Biosciences (San Diego, CA); CHAPS, propidium iodide,
Fig. 1 FASN and the cell death decision circuitry controlled by the BCL-2 family. We envisioned that the functional interaction between
FASN-catalyzed endogenous fatty acid biogenesis and the BCL-2 family interaction network that controls the mitochondrial pathway of
apoptosis might be the basis for the differential sensitivity to FASN inhibitors (FASNis). The BCL-2 family can be divided into three classes,
namely the pro-apoptotic BAX/BAK proteins, the proapoptotic BH3-only proteins, and the pro-survival proteins, the latter inhibiting the
activity of the pro-apoptotic BCL-2 family members. Although historically those BH3-only proteins able to directly activate BAX/BAK have been
termed either “activators” and those targeting pro-survival proteins to indirectly activate BAX/BAK have been called “sensitizers”, this strict
categorization is no longer appropriate as some “sensitizers” can exhibit direct activation functions under certain circumstances. Thus, BH3-
only proteins can be better distinguished by their ability to either directly bind and “activate” BAX/BAK or indirectly “derepress” pro-survival
proteins (via hindering the ability of pro-survival proteins to sequester BH3-only proteins to stop them activating BAX/BAK or impeding the
ability of pro-survival proteins to bind to activated BAX/BAK and prevent their homo-oligomerization). BAX/BAK activation ultimately controls
mitochondrial outer membrane permeabilization (MOMP), which precedes the release of mitochondria-stored cytochrome c (Cyt c) into the
cytosol to promote apoptosome formation, subsequent activation of effector caspases, and apoptosis. The balanced interactions within the
BCL-2 family involving activation of BH3-only proteins and inhibition by pro-survival proteins lastly sets how close a cell is to the threshold or
apoptosis, a property called “mitochondrial priming”. Lack or low levels of activating/de-repressing events upon exposure to FASNis might
lead to a resistant or unprimed state. When FASN blockade drives a high mitochondrial priming, cancer cells might acquire a primed-for-death
state in which they ensure their survival by becoming “addicted” to anti-apoptotic proteins sequestering pro-apoptotic members. Created
with BioRender.com.
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dimethyl pimelimidate, leupeptin, pepstatin, microcystin, sodium vanadate,
NaF, NAC, cerulenin and protein A-Sepharose from Sigma-Aldrich (St. Louis,
MO). The p38 inhibitor SB203580 (#5633) and the JNK inhibitor SP600125 (#42-
011-925MG) were purchased from Cell Signaling Technology Inc. (Danvers,
MA) and Fisher Healthcare (Waltham, MA), respectively. Anti-BAK (#12105),
anti-BAX (#2772), anti-BCL-2 (#2872), anti-BCL-XL (#2762), anti-MCL-1 (#45725),
and anti-BIM (#2819) antibodies were purchased from Cell Signaling
Technology, Inc. (Danvers, MA). Anti-FASN antibody (#610963) was purchased
from BD Transduction Laboratories™/BD Biosciences (San Jose, CA). Anti-NOXA
antibody (#114C307, #OP180) was purchased from Merck/Sigma-Aldrich. Anti-
PUMA (#28226) and β-actin (#1615 and #66009) were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA).
Constitution of palmitate-bovine serum albumin (BSA) and
BSA-C75 complexes
Palmitate (Sigma-Aldrich) was complexed with BSA. Palmitate was
dissolved in ethanol to 150mmol/L and diluted 1:5 in a 4% (w/v) BSA
solution in 0.9% NaCl and incubated for 1 h at 37°C to obtain a 30mmol/L
stock of BSA-complexed palmitate. C75 was then incubated with different
concentrations of palmitate-BSA complex for 9 h at 37°C and used for
experiments.
Annexin V binding by flow cytometry
Binding of APC-conjugated annexin V to cells was assessed by flow
cytometry. 20,000 events of pooled adherent and floating cells were
collected from the FL3 (excitation 488 nm, emission 650 LP) and FL4
(excitation 635 nm, emission 661 ± 8 nm) channels of a Becton Dickinson
Accuri C6 flow cytometer, and data were analyzed using Accuri C6Flow
software.
Assessment of intracellular ROS
Intracellular ROS production was monitored using the permeable
fluorescence dyes 5-(and-6)-carboxy-2,7-dichlorodihydrofluorescein diace-
tate (carboxy-H2DCFDA) (Invitrogen) and dihydroethidine (DHE) (Sigma-
Aldrich). Fluorescence intensity of intracellular DCF (excitation 488 nm,
emission 530 nm) or ethidium (excitation 488 nm, emission 585 nm) was
measured and analyzed by flow cytometry using Accuri C6Flow software.
Mitochondrial membrane potential
Changes in Δψm were estimated using a flow cytometer-based analysis
method for the JC-1 probe (Molecular Probes protocol: MitoProbe JC-1
assay kit for flow cytometry).
Cytochrome c release assay
Cytochrome c release was assayed using the InnoCyteTM Flow Cytometry
Cytochrome c Release Kit (Calbiochem, Los Angeles, CA).
Determination of NADPH/NADP+ ratio
The NADPH/NADP+ ratio was assessed using an NADP+/NADPH quanti-
fication kit (BioVision, Mountain View, CA).
Western blot analysis
Cells were harvested and lysed in 1× cell lysis buffer (Cell Signaling
Technology) containing protease and phosphatase inhibitors (Roche,
Indianapolis, IN) on ice for 30min with recurrent mixing every 5m. Protein
concentrations were determined using the Pierce BCA® protein assay kit
(Pierce, Rockford, IL). Cell lysates aliquots were resolved on 4–15%
polyacrylamide gels (Criterion TGX precast Gel; Bio-Rad, Hercules, CA) and
transferred to PVDF membranes. Membranes were blocked with 5% BSA for
1 h at RT and incubated with primary antibodies overnight at 4°C. Membranes
were washed 3 times with TBS-T, incubated with horseradish peroxidase-
linked secondary antibodies (1:4,000) for 1 h at RT, and visualized using
enhanced chemoluminescence reagent (Pierce) and Hyperfilm.
Quantitative reverse transcriptase-polymerase chain reaction
RNA was isolated using the Qiagen RNEasy plus mini kit. Analysis was
performed in triplicate using RNA (100 ng) and TaqMan One-Step RT-PCR
Master Mix (Applied Biosystems, Carlsbad, CA). Probe sets were: Noxa
(Hs00560402_m1), Bim (Hs00197982_m1), Puma (Hs00248075_m1), Bid
(Hs00609632_m1), Bik (Hs00154189_m1), Bax (Hs00180269_m1), Bak
(Hs00832876_g1), Bcl-2 (Hs00608023_m1), Bcl-xL (Hs00236329_m1), and
Mcl-1 (Hs03043898_m1). PCR was performed on the ABI Prism 7900HT real-
time system using a program consisting of 48°C for 30min, 95°C for 10min,
then 40 cycles of 95°C for 15 s and 60°C for 1min. Data analyses were
performed using the following equations: ΔCt= Ct(sample)− Ct(endogenous
control); ΔΔCt=ΔCt(sample)−ΔCt(untreated); and fold change= 2-ΔΔCt.
Small interfering RNA (siRNA) transfection
RNA interference was performed using siRNAs directed against: Noxa (5′-
GGAGAUUUGGAGACAAACU-3′), Puma (5′-GCCUGUAAGAUACUGUAUA-3′),
or Bim (5′-GACCGAGAAGGUAGACAAU-3′), all from Ambion (Austin, TX). On
day one, 1 × 107 cells were suspended in 370 μL of medium containing
1mmol/L oligonucleotides and subjected to electroporation using a BTX
830 square wave electroporator (BTX, San Diego, CA) delivering a single
pulse at 200mV for 10m. Twenty-four hours after transfection, cells were
treated with diluent or C75 for an additional 48 h and then assayed for
annexin V binding by flow cytometry.
Dynamic BH3 profiling
Dynamic BH3 profiling experiments were performed as previously
described [26–28].
Cell viability assays
Cell viability effects were determined using the standard colorimetric MTT
reduction assay.
Xenograft studies
Xenografts were established by injecting 2 × 106 BT-474 cells subcutaneously
into ovariectomized 3- to 4-week-old athymic female nude-Doxn1nu mice
(Harlan Sprague Dawley, Madison, WI) subcutaneously implanted with slow-
release estrogen pellets (Innovative Research) around left forearm using a trocar.
Once tumor engraftment was confirmed (>100mm3), mice (n= 10 per group)
were randomly allocated to each of the following treatment groups: Group A: (i.)
Vehicle (PEG-400), (ii.) TVB-3664 (2mg/kg/day/oral), (iii.) ABT-199 (100mg/kg/
day/oral), and (iv.) TVB-3664 (2mg/kg/day/oral)+ABT-199 (100mg/kg/day/oral);
group B: (i.) Vehicle (PEG-400), (ii.) TVB-3664 (2mg/kg/day/oral) alone, (iii.) ABT-
263 (100mg/kg/day/oral) alone, and (iv.) TVB-3664 (2mg/kg/day/oral)+ABT-
263 (100mg/kg/day/oral). For oral dosing, TVB-3664 was formulated in 100%
PEG-400 and diluted with water to a final PEG concentration of 30%
immediately before dosing. Tumor volume was calculated by 3D measurements
using the formula: tumor volume (mm3)= (length×width×height)/2. Tumor
volume values (mean± S.D.) were calculated weekly over a 4 week-period for
each experimental group using a Vernier caliper.
Statistical analysis
At least three independent experiments were performed with n≥ 3 replicate
samples per experiment. Data are presented as mean ± S.D. Student’s t test
was used to compare the means between two groups; comparisons of means
of ≥3 groups were performed by one-way ANOVA and Dunnett’s t-test for
multiple comparisons using GraphPard Prism (GraphPad Software, San Diego,
CA). P-values <0.05 and <0.005 were considered to be statistically significant
(denoted as * and **, respectively). All statistical tests were two-sided.
RESULTS
The extent of FASN inhibition-induced apoptotic cell death
relates to FASN expression status
We first examined apoptotic cell death using the semi-synthetic
FASNi C75 in three breast cancer cellular models expressing distinct
levels of FASN: BT-474 »> MCF-7 > MDA-MB-231 (Fig. 2a, inset).
C75 significantly and dose-dependently increased the number of
annexin V-positive BT-474 cells relative to vehicle-treated control cells
(Fig. 2a). A drastically smaller but still significant increase in annexin
V-positive cells was observed in C75-treated MCF-7 and MDA-MB-231
cells. Equivalent findings were found when using the natural FASN
inhibitor cerulenin (Fig. S1a).
FASN inhibition promotes ROS-dependent mitochondrial
cytochrome c release during apoptosis
We assessed whether FASN inhibition was accompanied by changes
in two apoptosis-related readouts, namely mitochondrial
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transmembrane potential (Δψm) and cytochrome c release [29–32].
All three cell lines responded to C75 with a dose-dependent increase
in the number of cells positive for JC-1 green fluorescence (Fig. 2b),
indicating mitochondrial membrane depolarization. C75-induced
loss of Δψm was prevented by N-acetylcysteine (NAC) [33, 34]
(Fig. 2b), suggesting a role for ROS in the loss of Δψm upon FASN
blockade. ROS production was significantly increased by C75 in BT-
474 and MCF-7 cells, but not in MDA-MB-231 cells, as revealed by
DCF staining (data not shown).
A time-dependent release of cytochrome c was observed only
in FASNis-treated BT-474 cells but not in MCF-7 and MDA-MB-231
cells, as measured by flow cytometry (Fig. 2c, d). Co-treatment
with NAC treatment blocked the ability of the FASNi to induce
apoptotic cell death (Fig. 2e, Fig. S1b), and prevented ROS
production and cytochrome c release in FASNis-sensitive cancer
cells (Fig. 2d, e). Co-treatment with the FASN end-product
palmitate largely prevented C75-induced ROS production and
effectively protected BT-474 cells from apoptosis in a dose-
dependent manner (Fig. 2e).
FASN inhibition activates redox-sensing kinases
As ROS production commonly results from redox stress, and
considering that redox-associated NADPH is rapidly consumed by
FASN [24], we examined the effects of FASN inhibition on NADPH
accumulation. We found a dramatic, dose-dependent accumula-
tion of NADPH in BT-474 cells treated with C75 (Fig. S1c). C75
promoted a more modest increase in the NADPH/NADP+ ratio in
both MCF-7 and MDA-MB-231 cells (Fig. S1c).
Redox imbalance causes the activation of stress-related
proapoptotic kinases such as Jun N-terminal kinase (JNK) and
p38 mitogen-activated protein kinase (p38 MAPK) [35, 36].
Although with different activation dynamics that might reflect
the induction of stress responses to attenuate ROS-mediated JNK
activation, FASNi augmented the phosphorylation status of both
JNK and p38 MAPK, which was largely prevented by NAC (Fig.
S1d). FASN inhibition also strongly activated AMP-activated
protein kinase (AMPK), a key regulator of metabolism and survival
during energy stress that senses intracellular redox signals [37],
and this was prevented by NAC (Fig. S1d).
FASN inhibition upregulates pro-death BH3-only proteins
Using pooled populations of both adherent and dead floating
cells, we found that the expression of the multidomain anti-
apoptotic proteins BCL-2, BCL-XL, and MCL-1 remained mostly
unchanged following pharmacological inhibition of FASN activity
(Fig. 3a, S1e). C75 treatment resulted in a robust dose-dependent
upregulation of the BH3-only BCL2 members BIM, NOXA, and
PUMA at both protein and mRNA levels (Fig. 3a). Inhibition of p38
MAPK activity with SB203580 lessened the ability of C75 to
upregulate BIM, NOXA, and PUMA (Fig. S1f, g), indicating that ROS-
driven activation of stress-induced kinases is linked to the
induction of BH3-only proteins in FASN-inhibited cancer cells.
The protein synthesis inhibitor cycloheximide blocked the
activation of BH3-only proteins in C75-treated cells (Fig. S1f, g),
suggesting that their accumulation after FASN inhibition requires
de novo protein synthesis.
Fig. 2 FASN inhibition promotes high levels of apoptotic cell death in FASN-overexpressing breast cancer cells. a. BT-474, MCF-7, MDA-
MB-231 cells were treated with graded concentrations of C75 or vehicle (DMSO) for 48 h and apoptosis was evaluated by annexin V/
propidium iodide staining using two-color flow cytometry. The inset shown the expression of FASN protein in the three cell lines. b Flow
cytometry assessment of JC-1 fluorescence in cells treated with graded concentrations of C75 or vehicle (DMSO) for 48 h. Alternatively, cells
were treated with 7.5 μg/mL C75 in the absence or presence of 5mmol/L N-acetylcysteine (NAC). c Flow cytometry-based assessment of
mitochondrial cytochrome c following exposure to C75 (7.5 μg/mL). d Top. Representative immunofluorescence images of cytochrome c
staining in BT-474 cells treated with cerulenin in the absence or presence of N-acetylcysteine (NAC). Scale bar is 10 μm. Bottom. Flow
cytometry-based assessment of mitochondrial cytochrome c following exposure to cerulenin in the absence or presence of NAC. e Left.
Quantification of apoptosis and reactive oxygen species (ROS) in BT-474 cells treated with C75 in the absence or presence of NAC or palmitate.
Right. Mitochondrial depolarization appears to be a common response to FASN inhibition irrespective of FASN status; however, the FASNi-
driven decrease in Δψm levels appears to have to reach a certain threshold to elicit the release of mitochondrial cytochrome c accompanying
apoptotic cell death, which is restricted to FASNi-sensitive cancer cells in an apparently ROS-dependent manner. All data are presented as
mean ± SD (n= 3), p < 0.05 and p < 0.005 (* and **, respectively).
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siRNA-mediated knockdown of BIM or NOXA significantly reduced
(up to 60 and 40% reduction, respectively) apoptotic cell death in
C75-treated BT-474 cells (Fig. 3b). siRNA-mediated depletion of
PUMA had less significant effect on C75-induced apoptosis. Although
those combinations containing the BIM-targeted siRNA (BIM/NOXA
and BIM/PUMA) were the most effective in preventing C75-induced
apoptotic cell death, the dual NOXA/PUMA silencing was also
capable of significantly reducing the extent of apoptosis in FASN-
inhibited cells (Fig. 3b). Palmitate rescued the downregulation of
FASN expression and the upregulation of BIM, NOXA, and PUMA in
response to C75 (Fig. S1h).
FASN status is a cancer cell-intrinsic determinant of
mitochondrial priming
FASN activity might regulate cancer cell survival by fine-tuning the
mitochondrial threshold for apoptosis, known as “mitochondrial
priming” [38–47]. To test this hypothesis, we took advantage of the
human near-haploid cell line HAP1 and its isogenic derivative
carrying a loss-of-function mutation in FASN as a suitable model
system for defective de novo FA synthesis [48]. We envisioned that
CRISPR/Cas9-mediated specific suppression of FASN might suffice to
drive early changes in the BCL-2 family of proteins preceding the
apoptotic process engagement, which can be detected by the
dynamic BH3 profiling assay [38, 39, 45]. The more “primed” a cell is,
the more sensitive its mitochondria will be to the synthetic BIM BH3
peptide, which promiscuously binds to all the anti-apoptotic BCL-2
family members and is a probe of overall mitochondrial priming. The
half-maximal concentration of the BIM peptide required to promote
cytochrome c release decreased by ~3-fold in FASN-KO cells
compared to FASN-expressing isogenic counterparts (Fig. 4a, left),
revealing that the BIM BH3 peptide permeabilized the mitochondria
more efficiently upon FASN depletion. Accordingly, FASN-KO cells
exhibited a Δ% priming of ~23% at 0.1 μmol/L BIM BH3 peptide. An
equivalent Δ% priming occurring in HAP1 cells treated with a sub-
optimal concentration of the FASNi C75 (5 μg/mL) was largely
prevented in FASN-KO HAP1 cells (Fig. 4a, left).
FASN inhibition enhances sensitivity to the BCL-2 family
inhibitor navitoclax/ABT-263
If FASN suppression elicits an enhanced mitochondrial priming
response, then FASNis should overcome resistance to BH3 mimetics
(Fig. 4a, right). We first questioned whether cancer cells treated with
C75 showed increased sensitivity to BH3 mimetic drugs such as the
dirty/promiscuous antagonist of BCL-2, BCL-XL, and BCL-W navito-
clax/ABT-263 [49, 50]. Whereas single-agent navitoclax failed to
trigger apoptotic cell death, addition of C75 noticeably synergized
(2–3-fold) with navitoclax/ABT-263 (Fig. 4b). This ability involved a
synergistic amplification of ROS generation (Fig. S1i). In SKBR-3 cells,
which express the highest cellular levels of FASN (up to 28% by
weight of the cytosolic proteins) yet described in human established
cell lines [26, 27, 51, 52], a clear apoptotic synergism was observed
when C75 was added to navitoclax/ABT-263, which had no impact
against SKBR-3 cells as single agent (Fig. 4b). The apoptosis-resistant
phenotype of low/moderate-FASN expressing MDA-MB-231 and
Fig. 3 BH3-only proteins mediate FASN inhibition-induced apoptosis. a FASN inhibition activates pro-apoptotic BH3-only proteins. Left.
Representative immunoblot analysis of NOXA, BIM, PUMA, BAK, BAX, BCL-2, MCL-1, and FASN in cell lysates from BT-474 cells treated with
graded concentrations of C75 for 48 h. Right. Q-PCR analyses of the expression of Bim, Noxa, and Puma. Before RNA extraction, cells were
treated with C75 in the presence of the pan caspase inhibitor Q-VD-OPh (5 µmol/L) for 48 h, collected by trypsinization, sedimented at 250×g
for 10min and frozen on dry ice. Data are presented as mean ± SD (n= 3), p < 0.05 and p < 0.005 (* and **, respectively). b. Depletion of BH3-
only proteins prevents FASNi-induced apoptotic cell death. Annexin V/propidium iodide staining-based flow cytometric assessment of
apoptotic cell death in C75-treated BT-474 cells previously transfected with either control, BIM, NOXA, or PUMA single siRNAs (top panels) or
their combinations (bottom panels). Annexin V+ cells data are presented as mean ± SD (n= 3), p < 0.05 and p < 0.005 (* and **, respectively).
Also shown are representative immunoblots (n= 3) of the BIM, NOXA, and PUMA knockdown efficiencies achieved by the corresponding
siRNAs.
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MCF-7 treated with navitoclax/ABT-263 remained unaltered by the
addition of C75 (Fig. S1j).
A clinical grade FASNi sensitizes cancer cells to the BCL-2-
specific BH3 mimetic venetoclax/ABT-199 in vitro
We explored the nature of the interaction between the recently
developed small-molecule FASNi TVB-3166 [12] and venetoclax/ABT-
199, an FDA-approved BH3 mimetic that specifically targets BCL-2
rather than multiple BCL proteins [53–55] (Fig. 4c). HAP1 FASN-KO cells
were largely refractory to the cytotoxic effects of TVB-3166 (Fig. S1k),
thereby demonstrating the FASN-dependent mechanism of action of
the TVB series of FASNis. Whereas single-agent venetoclax/ABT-199
failed to induce any significant level of apoptotic cell death, addition
of TVB-3166 dramatically enhanced the capacity of venetoclax/ABT-
199 to promote apoptotic cell death in BT-474 cells (Fig. 4c).
To definitely delineate the right BH3 mimetic that should
accompany a FASNi to work better in a clinical setting [56, 57], we
finally examined the nature of the apoptotic interaction between
mono-targeted BH3 mimetics and the TVB-3166-related molecule
TVB-3664—a close analog of the clinical-grade FASNi TVB-2640
[56–61]. Co-administration of TVB-3664 synergistically augmented
the apoptosis-inducing activity of the BCL-2 specific BH3-mimetic
Fig. 4 FASN inhibition exacerbates the pro-apoptotic activity of BCL2-targeting BH3 mimetics. a FASN is a determinant of mitochondrial
priming. Left. Dynamic BH3 profiling (DBP) assay of FASN-expressing HAP1 parental cells and HAP1 FASN-KO isogenic derivatives after treatment with
increasing concentrations of the BIM BH3 peptide. Representative immunoblot analysis of FASN in cell lysates from HAP1 FASN+ parental cells and
HAP1 FASN-KO isogenic derivatives. Results expressed as Δ% priming represents the increase in priming compared to FASN-containing HAP1 control
cells. Δ% priming after 16 h incubation with C75 was measured by enhanced BIM-induced cytochrome c release compared to DMSO-treated
controls. Data are presented as mean ± SD (n= 4). Right. Mitochondrial priming is depicted as proximity to the “cliff’s edge” (i.e., the apoptotic
threshold). FASN-expressing cells (FASN+ ) are at distance A from the edge. FASN suppression/inhibition causes mitochondrial membrane
depolarization (an early event in the onset of apoptosis). The distance that FASN inhibition pushes the cells towards the clifftop is represented by
the movement B, which is sufficient to push the cells to the clifftop (B≥ A). This model predicts that the ability of FASN-inhibited cells to cross the
apoptotic threshold and fall to the “cell death valley” can be accelerated in the presence of BH3 mimetics, which promote a deepening of the slope
towards the valley (B » A). Created with BioRender.com. b, c, d Annexin V/propidium iodide staining-based flow cytometric assessment of apoptotic
cell death in BT-474 and SKBR3 cells treated with FASNis (C75, TVB-3166, TVB-3664) in the absence or presence of ABT-263, ABT-199, S63845, and
A-1331852. Representative experiments showing the percentage of annexin V-positive cells in each experimental condition and quantification of
apoptosis are shown. Data are presented as mean ± SD (n= 3), p < 0.05 and p< 0.005 (* and **, respectively).
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Fig. 5 FASN inhibition sensitizes human breast tumor xenografts to BCL-2-targeting BH3 mimetics. a Left. Growth of BT-474 xenograft
tumors in athymic female mice treated with BH3 mimetics navitoclax/ABT-263 (top) and venetoclax/ABT-199 (bottom) in the absence or
presence of the FASNi TVB-3664. The maximum length for each treatment was 63 days. Results are presented as the mean tumor volume ± S.
D. (n= 10 mice/experimental group). Tumor growth inhibition (TGI) was calculated as the percentage of tumor growth, relative to tumor size
at the start of treatment, in drug-treated groups compared to vehicles-treated group. Right. In vivo findings from the HER2+ /FASN-
overexpressing breast cancer model BT-474 uncovers a novel FASN-dependent mitochondrial priming that links de novo FA biosynthesis to
the intrinsic apoptotic threshold in breast cancer cells. The discovery that FASN-inhibited cancer cells exist in an apoptosis-prone state highly
sensitive to BCL-2-targeting BH3 mimetics might warrant clinical exploration in patients with HER2+ /FASN-addicted breast carcinomas (see
the discussion section). FASN inhibition increases mitochondrial priming and enhances breast cancer cell sensitivity to BCL2-targeting BH3
mimetics: a working model (b). FASN-inhibited breast cancer cells exhibit an exacerbated apoptotic sensitivity to BH3 mimetics. In FASN-
addicted cancer cells, FASNis promote increased levels of pro-apoptotic activators such as BIM, thereby poising these cells ready for apoptotic
cell death. However, FASN-inhibited cells can survive with high mitochondrial priming because they become “addicted” to the expression of
anti-apoptotic proteins such as BCL-2 to sequester BIM and ensure survival. Cancer cell death will occur if the sequestration capacity of anti-
apoptotic proteins is exceeded by levels of pro-apoptotic proteins, which can be pharmacologically achieved with BH3 mimetic drugs capable
of disrupting the ability of anti-apoptotic BCL-2 family members to neutralize BH3-only proteins-driven activating events. Specifically, co-
administration of a FASNi synergistically augments the apoptosis-inducing activity of the dual BCL-XL/BCL-2 inhibitor ABT-263 (navitoclax) and
the BCL-2 specific BH3-mimetic ABT-199 (venetoclax). FASN inhibition, however, fails to sensitize breast cancer cells to MCL-1- and BCL-XL-
selective inhibitors such as S63845 and A1331852. Adapted from “MCL-1 Inhibition for Leukemia Treatment” by BioRender.com (2021).
Retrieved from https://app.biorender.com/biorender-templates.
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venetoclax/ABT-199 (Fig. 4d). TVB-3664, however, failed to
sensitize breast cancer cells to BH3-mimetics mono-targeting
MCL-1 (S63845) and BCL-XL (A1331852) (Fig. 4d) [62].
A clinical grade FASNi enhances sensitivity to navitoclax/ABT-
263 and venetoclax/ABT-199 in vivo
We finally sought to determine the efficacy of combining
navitoclax/ABT-263 or venetoclax/ABT-199 with TVB-3664 against
BT-474 human breast cancer xenografts in nude mice. BH3
mimetics and TVB-3664 were administered by oral gavage to
mimic human oral drug administration. Both navitoclax/ABT-263
and venetoclax/ABT-199 failed to elicit any tumor growth delay of
BT-474 xenograft tumors; notably, single agent TVB-3664 was
notably efficacious in producing a tumor response (44% tumor
growth inhibition) (Fig. 5a). The completely lack of anti-tumor
efficacy of navitoclax/ABT-263 and venetoclax/ABT-199 as single
agents was fully circumvented when FASN activity was pharma-
cologically targeted in BT-474 tumor xenografts; thus, when
administered in combination with the FASNi TVB-3664, navitoclax/
ABT-263 and venetoclax/ABT-199 caused strong tumor growth
inhibition (80% and 78%, respectively; Fig. 5a). Combination
therapy appeared to be well-tolerated, with mice maintaining
normal body weight (Fig. S1k).
DISCUSSION
A major roadblock to the clinical application of FASNis is that the
mechanism behind the resistance versus sensitivity of cancer cells
to death signaling triggered by FASN blockade remained poorly
understood [11–14]. We here show the ability of FASN activity to
dictate how close a cell is to the threshold of apoptosis, a
property called mitochondrial priming [38–48]. Mitochondria in
FASN-inhibited cancer cells exist in a primed-for-death state that
offers a novel therapeutic opportunity to treat breast cancer by
inducing hypersensitization to pro-apoptotic BH3 mimetic drugs
(Fig. 5b).
The fate of cancer cells exposed to FASNis might depend on
their proximity to an apoptotic threshold. Elevated levels of BCL-2-
like pro-survival proteins bound to pro-apoptotic family members
(e.g., BIM) appear to prepare cancer cells for apoptosis following
FASNi. Cell death induced by FASNis is diminished by concurrent
loss of pro-apoptotic proteins, suggesting that FASN activity
regulates cancer cell survival by fine-tuning the mitochondrial
threshold for apoptosis. Thus, while FASNis may not overtly affect
cancer cell viability, they heighten mitochondrial priming, which
shifts cancer cells towards a primed-for-death state that is
addicted to anti-apoptotic proteins to ensure survival but allows
a BH3-mimetic to unleash the mitochondrial pathway of
apoptosis. Specifically, counteracting the binding of pro-
apoptotic proteins with BH3-mimetics antagonizing BCL-2 (navi-
toclax and venetoclax) rather than MCL-1 (S63845) and/or BCL-XL
(A1331852) abolishes this protected state (Fig. 5b), leading to
increased apoptosis in FASN-inhibited cancer cells.
BCL-2-targeting BH3 mimetics alone have shown promising
activity in hematological malignancies, but they have been mostly
ineffective for solid tumors [63]. The response to BH3 mimetics
requires the alteration of the proapoptotic/antiapoptotic balance of
BCL-2 members through concomitant exposure to chemotherapy,
hormone therapy, or mTOR inhibitors [64–66]. Here, FASNi-
promoted upregulation of pro-apoptotic BH3-only proteins was
rescued by the FASN end-product palmitate, revealing that
starvation of endogenously produced FAs should be added to the
list of metabolic stresses capable of eliciting mitochondrial priming
and augmented responsiveness to BH3 mimetics [67–71]. Regardless
of the interconnected hierarchical model explaining how the BCL-2
family proteins dictate cellular survival versus mitochondrion-
dependent cell death [72–76], we now provide solid evidence that
intrinsic/primary unresponsiveness of cancer cells to BCL2-targeting
BH3 mimetics can be circumvented by promoting a high
mitochondrial primed-for-death state with FASNis.
The in vivo efficacy data in a xenograft cancer model validating
the actionable synergistic interaction between a clinical grade-like
FASNi and the BH3 mimetics ABT-263/navitoclax and venetoclax/
ABT-199 strongly support the exploration of their combination in
the clinic. Transcriptomic and proteomic data have confirmed that
HER2+ breast tumors are the highest FASN-expressors among
breast cancer subtypes [77–81]. The HER2-FASN lipogenic axis
therefore delineates a subgroup of patients that might benefit
from therapeutic regimens containing FASNis and BCL-2 BH3
mimetics. The recent discovery that brain metastases in HER2+
breast cancer patients rely on FASN [82, 83] illuminates the
important translational impact of combining blood–brain–barrier
penetrable versions of FASNis and BCL-2 BH3 mimetics such as
venetoclax, which has already shown a potential efficacy in the
treatment of malignancies with central nervous system involve-
ment [84–86].
CONCLUSIONS
We here add FASN-dependent endogenous lipogenesis to the list
of metabolic pathways closely intertwined with apoptotic cell
death in cancer cells. We propose that heightened mitochondrial
priming is the basis for the apoptotic hypersensitivity of cancer
cells starved of FASN-synthesized de novo FAs. Thus, the capacity
of FASN activity to regulate mitochondrial priming correlates with,
and may be a determinant of the therapeutic index of FASNis. Our
findings support a mitochondrial basis to explore the actionable
synergistic interaction between FASNis and BH3-mimetics target-
ing BCL-2 in the clinic setting.
DATA AVAILABILITY
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